Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.

Abstract: A perspiration garment comprises a top portion being configured for covering an upper portion of a user's body and for being adorned beneath exterior garments. The top portion comprises a non-breathable material being configured for covering a portion of the user's arms and torso for inducing perspiration. A bottom portion is configured for covering a lower portion of a user's body and for being adorned beneath exterior garments. The lower portion comprises a non-breathable material being configured for covering a portion of the user's legs for inducing perspiration, in which the top portion and the bottom portion are disposable and biodegradable.

Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.

Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.

Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.

Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.

Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.

Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.

Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.

Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.

Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.

Abstract: Methods for screening for agents capable of modulating human neuromedin U receptor 2 (NMUR2) activity are provided, as well as therapeutic methods for treating NMUR2-mediated conditions. More specifically, methods are provided for identifying agents capable of inhibiting NMUR2-mediated pain or nociception.

Abstract: Provided is a human RE2-L protein, as well as the encoding nucleic acid, methods for screening for agents capable of modulating RE2-L related activity and treating RE2-L-mediated conditions. Further provided are animal models useful for screening agents capable of ameliorating or reducing anxiety related disorders and obsessive-compulsive disorders.

Abstract: Methods for treating or alleviating pain by treating a subject in need thereof with an agonist of OPSDL3 activity or expression. Further provided are screening methods for identifying agents capable of activating OPSDL3, and transgenic non-human animals which homozygous for deletion of the endogenous OPSDL3 gene and/or comprise a human OPSDL3 gene.

Abstract: Provided is a human Calcium Independent Receptor of Latrotoxin 3-Like (CIRL3-L) protein, as well as the encoding nucleic acid, methods for screening for agents capable of modulating CIRL3-L related activity and treating CIRL3-L-mediated conditions. Further provided are animal models useful for screening agents capable of ameliorating or reducing anxiety related disorders, obsessive-compulsive disorders, seizure related disorders and autism and other pervasive developmental disorders.

Abstract: A non-animal based mixture of components serves as a control for complete blood count (CBC) analysis instruments and paraphernalia. The centrifugible non-animal based mixture simulates blood, and contains blood cell-simulating and other blood constituent-simulating components which are present in the mixture in controlled and known amounts. The mixture can be gravimetrically separated into its blood constituent-simulating components so as to serve as a control that simulates a centrifuged blood sample, and is thus used to check the accuracy of CBC blood analysis instruments, such as those marketed by Becton Dickinson and Company, under the trademark “QBC”.

Abstract: A non-animal based mixture of components serves as a control for complete blood count (CBC) analysis instruments and paraphernalia. The centrifugible non-animal based mixture simulates blood, and contains blood cell-simulating and other blood constituent-simulating components which are present in the mixture in controlled and known amounts. The mixture can be gravimetrically separated into its blood constituent-simulating components so as to serve as a control that simulates a centrifuged blood sample, and is thus used to check the accuracy of CBC blood analysis instruments, such as those marketed by Becton Dickinson and Company, under the trademark “QBC”.